Mirae Asset Global Investments Co., Ltd. Denali Therapeutics Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,178 shares of DNLI stock, worth $127,844. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,178
Previous 4,258
21.61%
Holding current value
$127,844
Previous $98,000
53.06%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$330 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$325 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$276 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$265 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$195 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...